Pharmacokinetics of SAR441236

Sponsor
National Institute of Allergy and Infectious Diseases (NIAID) (NIH)
Overall Status
Recruiting
CT.gov ID
NCT03705169
Collaborator
Sanofi (Industry)
84
27
17
43.3
3.1
0.1

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of SAR441236, a tri-specific broadly neutralizing antibody against the human immunodeficiency virus (HIV).

Condition or Disease Intervention/Treatment Phase
  • Biological: SAR441236
  • Biological: Placebo
  • Drug: Antiretroviral treatment
Phase 1

Detailed Description

This study will evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of SAR441236, a tri-specific broadly neutralizing antibody against HIV.

The study includes three arms. In Arm A, three cohorts of antiretroviral-treated, virologically suppressed participants will be randomized to receive a single intravenous (IV) dose of SAR441236 or placebo on Day 0. After Cohort 1, each subsequent cohort will open for enrollment only after an evaluation of safety outcomes for all participants in the previous cohort indicates that it is safe to increase the dose of SAR441236. All participants in Cohorts 1-3 will be followed for 24 weeks.

In Arm A, Cohort 4, participants will be randomized to receive an IV infusion of SAR441236 or placebo once every 12 weeks beginning at entry, for a total of 4 infusions. Participants in this cohort will be followed for 36 weeks after their final infusion.

Participants in Arm A will continue taking non-study-provided antiretroviral treatment throughout the study.

In Arm B, five cohorts of viremic participants will each receive a single IV dose of SAR441236 on Day 0. Each subsequent Arm B cohort will be opened for enrollment only after an evaluation of efficacy data from Day 14 for all participants in the previous cohort. All Arm B participants will be followed for 24 weeks.

Participants in Arm B will initiate or re-initiate non-study-provided combination antiretroviral therapy (ART) (selected by their primary HIV clinician) on Day 28.

In Arm C, two cohorts of ART-treated, virologically suppressed participants each will be randomized to receive a single subcutaneous (SC) dose of SAR441236 or placebo on Day 0. Cohort 11 will open for enrollment only after an evaluation of safety outcomes from Day 14 for all participants in Cohort 10 and the cumulative data from all the previous cohorts indicates it is safe to dose escalate. All Arm C participants will be followed for 24 weeks.

Participants in Arm C will continue taking non-study-provided ART throughout the study.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
84 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
A Phase I, First-in-Human Study of SAR441236, a Tri-specific Broadly Neutralizing Antibody, in Participants With HIV
Actual Study Start Date :
Apr 22, 2019
Anticipated Primary Completion Date :
Nov 30, 2022
Anticipated Study Completion Date :
Nov 30, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Arm A, Cohort 1A: SAR441236

In addition to continuing non-study-provided ART, participants will receive 1 mg/kg of SAR441236, administered as a single intravenous (IV) infusion on Day 0.

Biological: SAR441236
Administered by intravenous (IV) infusion or subcutaneous (SC) injection

Drug: Antiretroviral treatment
Antiretroviral treatment will be prescribed by participants' primary HIV clinician. It is not provided by the study.

Experimental: Arm A, Cohort 1B: Placebo for SAR441236

In addition to continuing non-study-provided ART, participants will receive placebo administered as a single IV infusion on Day 0.

Biological: Placebo
Administered by intravenous (IV) infusion or subcutaneous (SC) injection

Drug: Antiretroviral treatment
Antiretroviral treatment will be prescribed by participants' primary HIV clinician. It is not provided by the study.

Experimental: Arm A, Cohort 2A: SAR441236

In addition to continuing non-study-provided ART, participants will receive 3 mg/kg of SAR441236, administered as a single IV infusion on Day 0.

Biological: SAR441236
Administered by intravenous (IV) infusion or subcutaneous (SC) injection

Drug: Antiretroviral treatment
Antiretroviral treatment will be prescribed by participants' primary HIV clinician. It is not provided by the study.

Experimental: Arm A, Cohort 2B: Placebo for SAR441236

In addition to continuing non-study-provided ART, participants will receive placebo administered as a single IV infusion on Day 0.

Biological: Placebo
Administered by intravenous (IV) infusion or subcutaneous (SC) injection

Drug: Antiretroviral treatment
Antiretroviral treatment will be prescribed by participants' primary HIV clinician. It is not provided by the study.

Experimental: Arm A, Cohort 3A: SAR441236

In addition to continuing non-study-provided ART, participants will receive 10 mg/kg of SAR441236, administered as a single IV infusion on Day 0.

Biological: SAR441236
Administered by intravenous (IV) infusion or subcutaneous (SC) injection

Drug: Antiretroviral treatment
Antiretroviral treatment will be prescribed by participants' primary HIV clinician. It is not provided by the study.

Experimental: Arm A, Cohort 3B: Placebo for SAR441236

In addition to continuing non-study-provided ART, participants will receive placebo administered as a single IV infusion on Day 0.

Biological: Placebo
Administered by intravenous (IV) infusion or subcutaneous (SC) injection

Drug: Antiretroviral treatment
Antiretroviral treatment will be prescribed by participants' primary HIV clinician. It is not provided by the study.

Experimental: Arm A, Cohort 4A: SAR441236

In addition to continuing non-study-provided ART, participants will receive 30 mg/kg of SAR441236, administered as an IV infusion on Day 0 and then every 12 weeks (at weeks 12, 24, and 36) for a total of four doses.

Biological: SAR441236
Administered by intravenous (IV) infusion or subcutaneous (SC) injection

Drug: Antiretroviral treatment
Antiretroviral treatment will be prescribed by participants' primary HIV clinician. It is not provided by the study.

Experimental: Arm A, Cohort 4B: Placebo for SAR441236

In addition to continuing non-study-provided ART, participants will receive placebo administered as an IV infusion on Day 0 and then every 12 weeks (at weeks 12, 24, and 36) for a total of four doses.

Biological: Placebo
Administered by intravenous (IV) infusion or subcutaneous (SC) injection

Drug: Antiretroviral treatment
Antiretroviral treatment will be prescribed by participants' primary HIV clinician. It is not provided by the study.

Experimental: Arm B, Cohort 5: SAR441236

Participants will receive 1 mg/kg of SAR441236, administered as a single IV infusion on Day 0. Antiretroviral treatment will be initiated or re-initiated by Day 28.

Biological: SAR441236
Administered by intravenous (IV) infusion or subcutaneous (SC) injection

Drug: Antiretroviral treatment
Antiretroviral treatment will be prescribed by participants' primary HIV clinician. It is not provided by the study.

Experimental: Arm B, Cohort 6: SAR441236

Participants will receive 3 mg/kg of SAR441236, administered as a single IV infusion on Day 0. Antiretroviral treatment will be initiated or re-initiated by Day 28.

Biological: SAR441236
Administered by intravenous (IV) infusion or subcutaneous (SC) injection

Drug: Antiretroviral treatment
Antiretroviral treatment will be prescribed by participants' primary HIV clinician. It is not provided by the study.

Experimental: Arm B, Cohort 7: SAR441236

Participants will receive 10 mg/kg of SAR441236, administered as a single IV infusion on Day 0. Antiretroviral treatment will be initiated or re-initiated by Day 28.

Biological: SAR441236
Administered by intravenous (IV) infusion or subcutaneous (SC) injection

Drug: Antiretroviral treatment
Antiretroviral treatment will be prescribed by participants' primary HIV clinician. It is not provided by the study.

Experimental: Arm B, Cohort 8: SAR441236

Participants will receive 30 mg/kg of SAR441236, administered as a single IV infusion on Day 0. Antiretroviral treatment will be initiated or re-initiated by Day 28.

Biological: SAR441236
Administered by intravenous (IV) infusion or subcutaneous (SC) injection

Drug: Antiretroviral treatment
Antiretroviral treatment will be prescribed by participants' primary HIV clinician. It is not provided by the study.

Experimental: Arm B, Cohort 9: SAR441236

Participants will receive 0.3 mg/kg of SAR441236, administered as a single IV infusion on Day 0. Antiretroviral treatment will be initiated or re-initiated by Day 28.

Biological: SAR441236
Administered by intravenous (IV) infusion or subcutaneous (SC) injection

Drug: Antiretroviral treatment
Antiretroviral treatment will be prescribed by participants' primary HIV clinician. It is not provided by the study.

Experimental: Arm C, Cohort 10A: SAR441236

In addition to continuing non-study-provided ART, participants will receive 0.3 mg/kg of SAR441236, administered as a single subcutaneous (SC) injection on Day 0.

Biological: SAR441236
Administered by intravenous (IV) infusion or subcutaneous (SC) injection

Drug: Antiretroviral treatment
Antiretroviral treatment will be prescribed by participants' primary HIV clinician. It is not provided by the study.

Experimental: Arm C, Cohort 10B: Placebo for SAR441236

In addition to continuing non-study-provided ART, participants will receive placebo administered as a single SC injection on Day 0.

Biological: Placebo
Administered by intravenous (IV) infusion or subcutaneous (SC) injection

Drug: Antiretroviral treatment
Antiretroviral treatment will be prescribed by participants' primary HIV clinician. It is not provided by the study.

Experimental: Arm C, Cohort 11A: SAR441236

In addition to continuing non-study-provided ART, participants will receive 1 mg/kg of SAR441236, administered as a single SC injection or divided into multiple SC injections of a maximum of 2 mL per each syringe on Day 0.

Biological: SAR441236
Administered by intravenous (IV) infusion or subcutaneous (SC) injection

Drug: Antiretroviral treatment
Antiretroviral treatment will be prescribed by participants' primary HIV clinician. It is not provided by the study.

Experimental: Arm C, Cohort 11B: Placebo for SAR441236

In addition to continuing non-study-provided ART, participants will receive placebo administered as a single SC injection or divided into multiple SC injections of a maximum of 2 mL per each syringe on Day 0.

Biological: Placebo
Administered by intravenous (IV) infusion or subcutaneous (SC) injection

Drug: Antiretroviral treatment
Antiretroviral treatment will be prescribed by participants' primary HIV clinician. It is not provided by the study.

Outcome Measures

Primary Outcome Measures

  1. Occurrence of a Grade 3 or higher adverse event (AE) that is related to study treatment (as judged by the core safety team, blinded to active/placebo treatment in Arms A and C) any time from study treatment administration through the entire follow-up [Measured through 36 weeks after final infusion for Cohort 4]

    Based on the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), corrected Version 2.1, July 2017

  2. Occurrence of a Grade 3 or higher AE that is related to study treatment (as judged by the core safety team, blinded to active/placebo treatment in Arms A and C) any time from study treatment administration through the entire follow-up [Measured through Week 24 for Cohorts 1-3 and Arms B and C cohorts]

    Based on the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), corrected Version 2.1, July 2017

  3. AUC12wk of SAR441236 [Measured through Week 12]

    As assessed by pharmacokinetic sampling and analysis

  4. Change in plasma HIV-1 RNA (log10 copies/mL) from baseline (defined as the last measurement taken prior to the treatment initiation) to Day 7 of monotherapy for viremic participants with HIV (Arm B cohorts) [Measured through Day 7]

    Based on laboratory evaluations

Secondary Outcome Measures

  1. Change in plasma HIV-1 RNA (copies/mL) from baseline and post infusion for viremic participants with HIV (Arm B cohorts) [Measured through Day 28]

    Based on laboratory evaluations

  2. Change in plasma HIV-1 RNA (log10 copies/mL) from baseline (defined as the last measurement taken prior to treatment initiation) to Day 14 and Day 28 of monotherapy for Arm B cohorts [Measured through Day 28]

    Based on laboratory evaluations

  3. Maximum reduction of plasma HIV-1 RNA during 28 days of monotherapy for viremic participants with HIV (Arm B cohorts) [Measured through Day 28]

    Based on laboratory evaluations

  4. Attributions of anti-SAR441236 antibodies [Measured through Week 24 for Cohorts 1-3 and Arms B and C cohorts]

    Based on laboratory evaluations

  5. Attributions of anti-SAR441236 antibodies [Measured through 36 weeks after final infusion for Cohort 4]

    Based on laboratory evaluations

  6. Change in CD4+ T cell counts (cells/mm^3) from baseline to week 12 following single dose of SAR441236 for all cohorts [Measured through Week 12]

    Based on laboratory evaluations

  7. Change in CD4+ T cell counts (cells/mm^3) from baseline to week 12 following each infusion for Cohort 4 [Measured through 36 weeks after final infusion]

    Based on laboratory evaluations

  8. Maximum concentration of SAR441236 after infusion or SC injection for Cohorts 1-3 and Arm B and Arm C cohorts [Measured through Week 24]

    Based on laboratory evaluations

  9. Trough concentration of SAR441236 after infusion or SC injection for Cohorts 1-3 and Arm B and Arm C cohorts [Measured through Week 24]

    Based on laboratory evaluations

  10. Half life of SAR441236 after infusion or SC injection for Cohorts 1-3 and Arm B and Arm C cohorts [Measured through Week 24]

    Based on laboratory evaluations

  11. Time to half life of SAR441236 after infusion or SC injection for Cohorts 1-3 and Arm B and Arm C cohorts [Measured through Week 24]

    Based on laboratory evaluations

  12. Clearance of SAR441236 after infusion or SC injection for Cohorts 1-3 and Arm B and Arm C cohorts [Measured through Week 24]

    Based on laboratory evaluations

  13. Distribution volume of SAR441236 after infusion or SC injection for Cohorts 1-3 and Arm B and Arm C cohorts [Measured through Week 24]

    Based on laboratory evaluations

  14. Maximum concentration of SAR441236 after each infusion for Cohort 4 [Measured through 36 weeks after final infusion]

    Based on laboratory evaluations

  15. Trough concentration of SAR441236 after each infusion for Cohort 4 [Measured through 36 weeks after final infusion]

    Based on laboratory evaluations

  16. Half life of SAR441236 after each infusion for Cohort 4 [Measured through 36 weeks after final infusion]

    Based on laboratory evaluations

  17. Time to half life of SAR441236 after each infusion for Cohort 4 [Measured through 36 weeks after final infusion]

    Based on laboratory evaluations

  18. Clearance of SAR441236 after each infusion for Cohort 4 [Measured through 36 weeks after final infusion]

    Based on laboratory evaluations

  19. Distribution volume of SAR441236 after each infusion for Cohort 4 [Measured through 36 weeks after final infusion]

    Based on laboratory evaluations

  20. Establish concentration (or dose)-response relationship between SAR441236 exposure and changes in plasma HIV-1 RNA from entry baseline to week 4 (or viral load nadir) for Arm B cohorts [Measured through Week 4]

    Based on laboratory evaluations

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No

Inclusion Criteria, Arms A, B, and C

  • HIV-1 infection, documented by any licensed rapid HIV-1 test or HIV-1 enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by a licensed Western blot, Geenius assay, or a second antibody test by a method other than the initial rapid HIV-1 and/or E/CIA, or by HIV-1 antigen, plasma HIV-1 RNA viral load.

  • NOTE: The term "licensed" refers to a US Food and Drug Administration (FDA)-approved kit.

  • WHO (World Health Organization) and CDC (Centers for Disease Control and Prevention) guidelines mandate that confirmation of the initial test result must use a test that is different from the one used for the initial assessment. A reactive initial rapid test should be confirmed by either another type of rapid assay or an E/CIA that is based on a different antigen preparation and/or different test principle (e.g., indirect versus competitive), or a Western blot, Geenius assay, or a plasma HIV-1 RNA viral load.

  • The following laboratory values obtained within 45 days prior to entry by any US laboratory that has a Clinical Laboratory Improvement Amendments (CLIA) certification or its equivalent.

  • Absolute neutrophil count (ANC) greater than or equal to 1500 cells/mm^3

  • Hemoglobin greater than or equal to 12.0 g/dL for men and greater than or equal to 11.0 g/dL for women

  • Platelet count greater than or equal to 120,000/mm^3

  • Creatinine clearance (CrCl) greater than 60 mL/min

  • Refer to the calculator located on the FSTRF website (at https://www.frontierscience.org/): Calculated Creatinine Clearance - Cockcroft-Gault Equation (Adult).

  • Aspartate aminotransferase (AST) (SGOT) less than 1.25 x upper limit of normal (ULN)

  • Alanine aminotransferase (ALT) (SGPT) less than 1.25 x ULN

  • Alkaline phosphatase less than 2.0 x ULN

  • Total bilirubin less than 1.1 x ULN

  • Hepatitis C virus (HCV) antibody negative result within 45 days prior to study entry or, for study candidates who are HCV antibody positive (based on testing performed at any time prior to study entry), a negative HCV RNA result obtained within 45 days prior to study entry.

  • NOTE: A negative HCV RNA level may result from either spontaneous clearance or from HCV therapy. Participants must have completed any HCV therapy at least 6 months prior to enrollment.

  • Negative HBsAg result obtained within 45 days prior to study entry, or documented hepatitis B immunity, defined as positive hepatitis B surface antibody testing, at any time.

  • Female study candidates of reproductive potential must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL performed at screening and again within 24 hours before study entry by any US clinic or laboratory that has a CLIA certification or its equivalent, or is using a point of care (POC)/CLIA-waived test.

  • NOTE: Reproductive potential is defined as girls who have reached menarche, and women who have not been post-menopausal for at least 24 consecutive months, i.e., who have had menses within the preceding 24 months, and women who have not undergone surgical sterilization, specifically hysterectomy and/or bilateral oophorectomy.

  • All study candidates must agree not to participate in an assisted conception process (e.g., sperm donation, intrauterine insemination, in vitro fertilization) from screening until 12 weeks after the final study visit.

  • If participating in sexual activity that could lead to pregnancy, all study candidates must agree to use at least one reliable method of contraception from study entry until 12 weeks after the final study visit. At least one of the following methods must be used appropriately:

  • Condoms (male or female) with or without a spermicidal agent. Condoms are recommended because their appropriate use is the only contraception method effective for preventing HIV transmission.

  • Diaphragm or cervical cap with spermicide.

  • Intrauterine device.

  • Hormone-based contraceptive.

  • Study candidates who are not of reproductive potential are eligible without requiring the use of a contraceptive method. Acceptable documentation of sterilization, menopause, and reproductive potential is specified below.

  • Written documentation or oral communication from a clinician or clinician's staff documented in source documents of one of the following:

  • Physician report/letter

  • Operative report or other source documentation in the patient record

  • Discharge summary

  • Laboratory report of azoospermia (is required to document successful vasectomy)

  • Follicle-stimulating hormone (FSH) measurement elevated into the menopausal range as established by the reporting laboratory.

  • NOTE A: Female reproductive potential is defined in the criteria above.

  • NOTE B: Male candidates who are not of reproductive potential are defined as having documented azoospermia.

  • NOTE C: A female study candidate's oral report of her male partner's lack of reproductive potential should be recorded in the source documents if written proof is not available.

  • Individuals age greater than or equal to 18 years and less than or equal to 70 years at study entry.

  • Ability and willingness of participant to provide informed consent.

Additional Arms A- and C-specific Inclusion Criteria

  • Receiving combination ART for at least 12 months prior to study entry with no changes in ART regimen within the 12 weeks prior to entry.

  • NOTE A: Use of a two-drug ART regimen within the 12 months prior to entry is exclusionary.

  • NOTE B: Although ritonavir or cobicistat may be included in a combination ART regimen, neither of these "counts" in a tally of antiretroviral agents.

  • CD4+ cell count of greater than or equal to 200 cells/mm^3 obtained within 45 days prior to study entry at any US laboratory that has a CLIA certification or its equivalent.

  • Within 45 days prior to study entry, plasma HIV-1 RNA <50 copies/mL on any FDA-approved assay with a limit of quantification of <50 copies/mL by a US laboratory that has a CLIA certification or its equivalent.

  • Within 12 months prior to study entry and before screening, at least one documented plasma HIV-1 RNA <50 copies/mL on any FDA-approved assay with a limit of quantification of <50 copies/mL by a US laboratory that has a CLIA certification or its equivalent.

  • NOTE: A single plasma HIV-1 RNA ≥50 but <200 copies/mL at least 6 months prior to screening is permitted if followed within 2 months by an HIV-1 RNA <50 copies/mL.

Additional Arm B-specific Inclusion Criteria

  • Plasma HIV-1 RNA >5000 and ≤200,000 copies/mL within 45 days prior to study entry.

  • CD4+ cell count of greater than or equal to 350 cells/mm^3 obtained within 45 days prior to study entry at any US laboratory that has a CLIA certification or its equivalent.

  • Willingness and ability to start or re-start combination ART by or on Day 28 of the study.

Exclusion Criteria, Arms A, B, and C

  • Breastfeeding or plans to become pregnant.

  • Receipt of chimeric, humanized or human long-acting mAbs, whether licensed or investigational, within 12 months prior to entry, or receipt of chimeric, humanized or human regular mAbs, whether licensed or investigational, within 6 months prior to entry, unless reviewed and approved by the study's core team.

  • Known allergy/sensitivity or any hypersensitivity to components of study treatment or its formulation (refer to the product's Investigator's Brochure).

  • Vaccination within 30 days prior to entry or intent to receive an elective vaccination (e.g., hepatitis A vaccine, travel-related) during the course of the study except as noted in the study protocol.

  • Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.

  • Acute or serious illness requiring systemic treatment and/or hospitalization within 45 days prior to entry.

  • Diagnosis of AIDS-defining illness using the current list on the US Centers for Disease Control and Prevention (CDC) website within 1 year prior to entry.

  • Weight greater than 115 kg within 45 days prior to study entry.

  • Use of maraviroc, ibalizumab, or enfuvirtide at any time.

Additional Arms A- and C-specific Exclusion Criterion

  • Within 6 months prior to study entry, any plasma HIV-1 RNA ≥50 copies/mL on any FDA-approved assay with a limit of quantification of <50 copies/mL performed by a US laboratory that has a CLIA certification or its equivalent.

Additional Arm B-specific Exclusion Criterion

  • Use of any anti-HIV ART, including FDA-approved pre-exposure prophylaxis (PrEP) within the preceding 3 months

Additional Arm C-specific Exclusion Criterion

  • Presence of abdominal scarring or tattooing that could interfere with assessment of injection-site reaction.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Alabama CRS Birmingham Alabama United States 35294
2 UCLA CARE Center CRS Los Angeles California United States 90035
3 UCSD Antiviral Research Center CRS San Diego California United States 92103
4 Ucsf Hiv/Aids Crs San Francisco California United States 94110
5 Harbor-UCLA CRS Torrance California United States 90502
6 University of Colorado Hospital CRS Aurora Colorado United States 80045
7 The Ponce de Leon Center CRS Atlanta Georgia United States 30308-2012
8 Northwestern University CRS Chicago Illinois United States 60611
9 Rush University CRS Chicago Illinois United States 60612
10 Massachusetts General Hospital CRS (MGH CRS) Boston Massachusetts United States 02114
11 Brigham and Women's Hospital Therapeutics Clinical Research Site (BWH TCRS) CRS Boston Massachusetts United States 02115
12 Washington University Therapeutics (WT) CRS Saint Louis Missouri United States 63110-1010
13 New Jersey Medical School Clinical Research Center CRS Newark New Jersey United States 07103
14 Weill Cornell Chelsea CRS New York New York United States 10010
15 Columbia P&S CRS New York New York United States 10032-3732
16 Weill Cornell Uptown CRS New York New York United States 10065
17 University of Rochester Adult HIV Therapeutic Strategies Network CRS Rochester New York United States 14642
18 Chapel Hill CRS Chapel Hill North Carolina United States 27599
19 Cincinnati Clinical Research Site Cincinnati Ohio United States 45219
20 Case Clinical Research Site Cleveland Ohio United States 44106
21 Ohio State University CRS Columbus Ohio United States 43210
22 Penn Therapeutics, CRS Philadelphia Pennsylvania United States 19104
23 University of Pittsburgh CRS Pittsburgh Pennsylvania United States 15213
24 The Miriam Hospital Clinical Research Site (TMH CRS) CRS Providence Rhode Island United States 02906
25 Vanderbilt Therapeutics (VT) CRS Nashville Tennessee United States 37204
26 University of Washington AIDS CRS Seattle Washington United States 98104-9929
27 Puerto Rico AIDS Clinical Trials Unit CRS San Juan Puerto Rico 00935

Sponsors and Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)
  • Sanofi

Investigators

  • Study Chair: Athe Tsibris, MD, MS, Brigham and Women's Hospital, Harvard Medical School
  • Study Chair: Daniel R. Kuritzkes, MD, Brigham and Women's Hospital Therapeutics CRS, Harvard Medical School
  • Study Chair: Pablo Tebas, MD, Penn Therapeutics CRS

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT03705169
Other Study ID Numbers:
  • ACTG A5377
  • 38508
  • TDU15867
First Posted:
Oct 15, 2018
Last Update Posted:
Apr 22, 2022
Last Verified:
Apr 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
Yes
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID)
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 22, 2022